Summary
The pharmacokinetics of meptazinol (Meptid®) have been studied in nine male volunteers after single and multiple oral administration of 200 mg tablets and also after a single 25 mg intravenous dose. Plasma concentrations of meptazinol were determined by HPLC using fluorescence detection. Drug absorption after oral dosage was rapid, peak plasma concentrations being reached between 0.25 and 2 h after drug administration. Subsequent elimination proceeded in an apparently mono-exponential fashion with a half-life of 2 h, although after intravenous dosage there was evidence of an initial rapid distributive phase. The mean total plasma clearance was 2.21/min and the mean apparent volume of distribution (Vdβ) was 4.99 l/min. The bioavailability ranged from 1.9 to 18.5% (mean=8.7%) and was related to the rate of absorption. Multiple dosing, 6-hourly for 3 days, did not produce any accumulation above that predicted from a single dose. Plasma protein binding of the drug was 27.1% and did not vary over the therapeutic concentration range of 25 to 250 ng/ml.
Similar content being viewed by others
References
Brunk SF, Delle MS (1974) Morphine metabolism in man. Clin Pharmacol Ther 16: 51–57
Caruso FS, Pircio AW, Maddissoo H, Smyth RD, Pochter IJ (1979) Butorphanol. Pharmacol Biochem Prop Drug Subst 2: 19–57
Dowell PS, Pierce DM, Franklin RA, Robson PJ, Jackson MBA (1982) Routes of meptazinol conjugation in the neonate. Brit J Clin Pharmacol 14: 748–750
Ehrnebo M, Boréus LO, Lönroth U (1978) Bioavailability and first pass metabolism of oral pentazocine in man. Clin Pharmacol Ther 22: 883–892
Franklin RA, Aldridge A, White C de B (1976) Studies on the metabolism of meptazinol, a new analgesic drug. Br J Clin Pharmacol 3: 497–502
Franklin RA (1977) The influence of gastric emptying on plasma concentrations of the analgesic, meptazinol. Br J Pharmacol 59: 565–569
Frost T (1981) Determination of meptazinol in plasma by high performance liquid chromatography with fluorescence detection. Analyst 106: 999–1001
Heel RC, Brogden RN, Speight TM, Avery GS (1979) Buprenorphine: A review of its pharmacological properties and therapeutic efficacy. Drugs 17: 81–110
Jordan C, Lehane JR, Robson PJ, Jones JG (1979) A comparison of the respiratory effects of meptazinol, pentazocine and morphine. Br J Anaesth 51: 497–501
Mather LE, Tucker GT, Pflug AE, Lindop MJ, Wilkerson C (1974) Meperidine kinetics in man. Clin Pharmacol Ther 17: 21–30
Niazi S (1979) Textbook of biopharmaceutics and clinical pharmacokinetics. Prentice-Hall, New York, pp 141–173
Pearce V, Robson PJ (1980) Double-blind cross-over of oral meptazinol, pentazocine and placebo in the treatment of pain in the elderly. Postgrad Med J 56: 474–477
Rosseel MT, Bogaert MG, Verschraegen R, Staquet M (1976) Plasma concentrations of meptazinol (Wy 22811) after different routes of administration. Pharmatherapeutica 1: 270–276
Stephens RJ, Waterfall JF, Franklin RA (1978) A review of the biological properties and metabolic disposition of the new analgesic agent, meptazinol. Gen Pharmacol 9: 73–78
Ward PJ (1981) Double-blind comparison of meptazinol versus pentazocine in patients with chronic backache. Curr Ther Res 30: 507–514
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Norbury, H.M., Franklin, R.A. & Graham, D.F. Pharmacokinetics of the new analgesic, meptazinol, after oral and intravenous administration to volunteers. Eur J Clin Pharmacol 25, 77–80 (1983). https://doi.org/10.1007/BF00544019
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00544019